Based on exome and genotyping data for almost 200 Nunavik Inuit, researchers retraced the population's ancestry, relationship, adaptations, and aneurysm risk.
The teams used different sequencing approaches — one using long reads and the other short reads — to uncover repeat expansions in people with a rare disease.
Cowen and William Blair initiated coverage of Adaptive with Outperform ratings, while JP Morgan assigned an Overweight rating and a $45 price target to the firm's stock.
